Rapcabtagene autoleucel

N/A

Report date: 2026/05/21 20:00:22

Base Information

Drug NameRapcabtagene autoleucel
Drug Alias NameYTB-323
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Lentiviral vectorCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Donor > Autologous +[4] 
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsScleroderma, DiffuseLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[22] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesStanford UniversityNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsScleroderma, DiffuseLupus Erythematosus, SystemicAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis +[13] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A